文献速递淋巴瘤

慢性淋巴细胞白血病患者对mRNA抗COVID-19疫苗BNT162b2和mRNA-1273的体液免疫应答

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

研究纳入530例慢性淋巴细胞白血病患者,评估BNT162b2或mRNA-1273疫苗第1、2、3剂后及既往确诊COVID-19者单剂后的SARS-CoV-2特异性抗体应答。第1剂后应答率27%,第2剂后52%;第2剂后未治疗患者应答率最高(72%),接受BTK抑制剂单药(22%)或联合抗CD20单抗或维奈克拉(0%)者应答率较低,维奈克拉单药者应答率显著较高(52%)。多因素分析确定年龄>65岁、持续CLL治疗和γ球蛋白≤6 g/L为无血清转化的独立预测因素;第2剂后血清阴性者第3剂后总体应答率35%。

要点

  • 第1剂后应答率27%,第2剂后52%,第3剂后血清阴性者总体应答率35%。
  • 第2剂后未治疗患者应答率72%,化疗免疫治疗史者60%,BTK抑制剂单药者22%,BTK抑制剂联合抗CD20单抗或维奈克拉者0%,维奈克拉单药者52%。
  • 年龄>65岁、持续CLL治疗和γ球蛋白≤6 g/L为无血清转化的独立预测因素。

核心结论

  • 本研究为使用第三剂疫苗和预防性SARS-CoV-2中和单克隆抗体提供了论据。

研究设计与样本

  • 研究纳入530例慢性淋巴细胞白血病患者,评估BNT162b2或mRNA-1273疫苗第1、2、3剂后及既往确诊COVID-19者单剂后的SARS-CoV-2特异性抗体应答。
  • 患者间隔4周接受2剂,若第2剂后血清阴性则接受第三剂。

主要发现

  • 第1剂后应答率27%,第2剂后52%。
  • 第2剂后未治疗患者应答率最高(72%),其次为既往接受化疗免疫治疗的患者(60%)。
  • 接受治疗的患者中,BTK抑制剂单药(22%)或联合抗CD20单克隆抗体或维奈克拉(0%)者应答率较低,维奈克拉单药者应答率显著较高(52%)。
  • 多因素分析确定年龄>65岁、持续CLL治疗和γ球蛋白≤6 g/L为无血清转化的独立预测因素。
  • 第2剂后血清阴性患者第3剂后总体应答率35%。

临床怎么用

  • 本研究为使用第三剂疫苗和预防性SARS-CoV-2中和单克隆抗体提供了论据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL) are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses in patients with CLL after the first, second, and third doses of the BNT162b2 or mRNA-1273 vaccines and after a single dose for patients with confirmed previous COVID-19. In all, 530 patients were included in the study. Patients received 2 doses at a 4-week interval and a third dose if they were seronegative after the second dose. Response rate was 27% after dose 1 and 52% after dose 2. Post-dose 2 treatment-naïve patients had the highest response rate (72%) followed by patients previously treated by chemoimmunotherapy (60%). Among patients receiving therapy, those receiving Bruton tyrosine kinase inhibitor alone (22%) or in combination with anti-CD20 monoclonal antibodies or venetoclax (0%) had the poorer response rate whereas patients who received venetoclax monotherapy achieved a significantly higher response rate (52%). A multivariable analysis identified age older than 65 years, ongoing CLL treatment, and gamma globulin ≤6 g/L as independent predictors of the absence of seroconversion. Post-dose 2 seronegative patients had a global response rate of 35% after dose 3. This study provides an argument for the use of a third dose and for prophylactic SARS-CoV-2 neutralizing monoclonal antibodies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bagacean C, Letestu R, Al-Nawakil C, et al. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv. 2022. PMID: 34844264. doi:10.1182/bloodadvances.2021006215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。